A three-goal second period Saturday sparked the Garnet Chargers to a 4-1 ECAC Hockey victory over Brown at Messa Rink. It’s the final game of 2024 for Union (5-4-0 ECACH, 15 points; 8-11-1 overall). The Garnet Chargers return to action Jan. 3, when they host Quinnipiac. “I thought we played with a similar simplicity to our game,” Union coach Tony Maci, referencing the team’s play in Friday’s 3-1 loss to Yale, said during the postgame interview on ESPN+. “We were able to bury the chances.” Union took a 1-0 lead midway through the first period on an Amanda Quan goal. The Bears (4-7-1, 16.5 points; 8-7-1) tied it just over eight minutes into the second period when Monique Lyons scored on a two-player advantage. Nearly four minutes later, Kiara Kenttala gave Union a 2-1 lead. That ignited things for the Garnet Chargers. Stephanie Bourque scored a power-play goal with 6:10 left in the second. Maddie Leaney made it a three-goal advantage with 1:29 remaining in the period. Union goalie Sophie Matsioukas stopped 30 shots. “She made a couple big saves,” Maci said. “Good to see that same consistency from her again.” Brown 0 1 0 — 1 Union 1 3 0 — 4 First Period — 1, Union, Quan 1 (Jones), 11:57. Penalties — Muralt, Bro (hooking-penalty shot), 10:49; Broz, Brow (tripping), 16:08. Second Period — 2, Brown, Lyons 7 (Norehad, Muralt), 8:07 (pp). 3, Union, Kenttala 2 (Suitor, Adams), 11:58, 4, Union, Bourque 5 (Friday, Davidson), 13:50 (pp). 5, Union, Leaney 4 (Engelbert, Friday), 18:31. Penalties — Mauracher, Uni (cross-checking), 3:49; Union bench, served by Engelbert (too many players), 6:18; Davidson, Uni (body checking), 7:48; Fantino, Bro (boarding), 13:08. Third Period — None. Penalties — Jones, Uni (hitting from behind), 6:49; Hebert, Uni (tripping), 14:14. Missed penalty shot — Union, Mauracher, 10:49 1st. Shots on Goal — Brown 8-11-12 — 31. Union 13-8-3 — 24. Power-play opportunities — Brown 1 of 5; Union 1 of 2. Goalies — Brown, Zupkofska 2-3-1 (24 shots-20 saves). Union, Matsoukas 7-9-0 (31-30). A — 219. Referees — Tasha Adams, Michael St. Lawrence. Linesmen — Jackie Spresser, Sarah Buckner.
Rural Riches - Why Tractor Supply Is A Dividend Stock Worth Owning
Legion Go S spotted after Lenovo teases new AMD Ryzen gaming handhelds before CES 2025 event
Horizon Aircraft Secures $8.4 Million Strategic InvestmentRICHMOND — While Saturday’s Casey Pohlenz Memorial Tournament championship meant very little compared to the rest of the team’s goals, the Alexandria girls basketball team still had plenty to gain Saturday at the Tiernan Center. After romping to victory in its first 14 games, coach Mickey Hosier needed to know how his team would respond late in a tight game. Quite well appears to be the answer. Not long after surviving a double-overtime marathon against Class 3A Charlestown in the semifinal, Jacklynn Hosier scored 25 points and grabbed 11 rebounds as Alexandria stormed back from a nine-point second-half deficit to knock off 4A Richmond 49-45 and claim the championship. While far from perfect, the coach was all smiles after his team’s second comeback win in as many tries. “As you look at our season — us included — we just haven’t had to do that, and when you haven’t had to do it, you don’t know if you can do it,” he said. “I always thought we could do it. That’s why we got into this tournament was to get into situations like that.” For her efforts, Hosier earned the tournament’s MVP, and Tigers senior Rylie Kellams was also named to the all-tournament team. In the semifinal against Charlestown, Hosier’s supporting cast did much of the heavy lifting, but the Tigers needed Hosier at her very best in the second half to claim their 16th win of the season. Richmond’s Amyannah Tucker’s 3-point shot midway through the third quarter gave the Red Devils their biggest lead of the contest at 31-22 and had the Tigers, who had been held to just four points in the second quarter, very much on the ropes. But Trinity Ford started the comeback with a pair of free throws before Hosier scored off a Richmond missed basket. A Jazlyn Diamond basket for the Red Devils paused the Alex surge, but Hosier hit a pair of free throws to close the third quarter and two more to open the fourth before she found Kellams for a layup to pull the Tigers within one. Hosier was 8-for-8 from the free-throw line in the second half after missing three of her first four attempts in the first half, prompting an immediate eye-roll from the Vermont commit at the mention of the early misses. “It was frustrating because they’re free shots, and I know I can make them,” she said. “But I didn’t play well in the first half, and I knew my team needed me to be better in the second half, and I think everyone stepped up in the second half.” After the teams traded baskets, freshman Conleigh Davidson connected on a 3-point basket — her only field goal of the second game — on an assist from Hosier, and the Tigers had the lead for good at 38-36. A Lily Harpe layup and Hosier drive were sandwiched around a 3-pointer by Richmond’s Maren Bolser, and the Tigers led 42-39. Hosier drove to the basket and was fouled as her shot fell. She converted the charity toss and Alex was up six. Sophomore Stella Griffin and Harpe each made a pair of free throws in the closing moments to seal the title for the Tigers. The wins meant more to Hosier in terms of indicating what this team is capable of as opposed to maintaining the unbeaten mark. “I think we didn’t play our best, and we were throwing the ball away,” she said. “But I think the best thing we did was that we came together as a team, and I think you have to when it’s physical. We just had a lot of fight in this whole tournament.” With 19 points in the first game, Hosier also eclipsed the 1,800-point milestone for her career. Kellams scored 14 points in the first game of the day and finished with seven points and four rebounds against Richmond while Harpe scored nine points to go with three steals. Alexandria will now set its sights on the Madison County Tournament which, for the Tigers, begins Jan. 6 at nine-time champion Anderson at 6 p.m. The Tigers will be the first girls team to enter county tournament week unbeaten since the 2009 Lapel Bulldogs, who were 10-0, but lost to Highland in the first round. Although a semifinal matchup against pretournament favorite Pendleton Heights or two-time defending champion Lapel looms for Alexandria, Coach Hosier is not looking past Anderson (1-14) in that first-round game. “I think Pendleton is the favorite, I would say. They play a better schedule in 4A,” he said. “When you get into this county, it’s like a sectional, and you better bring your A-game. Our focus is totally on Anderson, and if we win that one, we’ll worry about the next one, whoever that is.”
Kash Patel: The die-hard loyalist
Drying clothes inside could be harming your health - here's how to fix it for just £1.25(Reuters) - U.S. President-elect Donald Trump and French President Emmanuel Macron shared an intense series of handshakes on Saturday, reminiscent of the white-knuckled grip-off that marked a meeting between the two leaders more than seven years ago. Visiting Paris to attend the reopening of the Notre-Dame cathedral, Trump was greeted by Macron at the steps of the Elysee Palace. It was Trump's first foreign trip since winning the Nov. 5 U.S. election. Exiting his vehicle, Trump pulled Macron's right hand towards his body as the two hugged and gripped each other with clenched fists, shaking firmly back and forth. While friendly, it appeared both men were holding on tight. As they ascended the steps of the palace and turned again towards the cameras, Trump positioned his hand above Macron's and pushed down firmly as they locked hands for a second time. The sequence triggered approval from some Trump supporters online, who saw in the president-elect's actions a concerted attempt to intimidate Macron. "President Trump is back to dominating world leaders with his handshake," an account who goes by the username @BehizyTweets posted on the social media platform X. "Macron is going to need a hand massage after all that twisting and pulling Trump did to him." The two men have a history of intense handshakes. When they met for the first time in May 2017 ahead of a NATO summit in Brussels, each man gripped each other's right hand so firmly that their knuckles turned white and their jaws seemed to clench as they sat for a face-to-face meeting. Macron told a newspaper in 2017 that the white-knuckle handshake was "not innocent" and "a moment of truth" aimed at showing his U.S. counterpart, whose first term ended in January 2021, that he would not be intimidated. Trump and Macron were joined later on Saturday by Ukraine's President Volodymyr Zelenskiy. The meeting occurred with world leaders in Paris to celebrate Notre-Dame's restoration five years after it was ravaged by fire. Trump and Macron shared another firm and prolonged handshake outside the cathedral, though it fell short of the intensity of the 2017 grip-off, according to social media influencer Collin Rugg. "The handshake battle between Donald Trump and Emmanuel Macron continues," Rugg posted on X. "Their handshake at the Notre Dame Cathedral lasted for 17 seconds, coming short of their previous record of 29 seconds." (Reporting by Nathan Layne in New York; Editing by Paul Simao)
Huntley fills in for injured Tagovailoa, leads Dolphins past Browns 20-3 to keep playoff hopes alive
The Latest: Former President Jimmy Carter is Dead at age 100Kalen DeBoer knows what’s at stake for Alabama against OklahomaShare the Spirit: Nonprofit helps homeless, impoverished East Bay military veterans feel like ‘not just a number’
‘I felt like I belonged’: Paddlers with disabilities find a second home in sport of dragon boat
ATLANTA (AP) — Jalen Johnson scored 28 points and the Atlanta Hawks closed out a four-game homestand, winning a third straight contest, 120-110 over the Miami Heat on Saturday. Trae Young added his 22nd double-double of the season, with 11 point and 15 assist, and De'Andre Hunter scored 26 points in his 14th consecutive game with at least 15 points coming off the bench. Tyler Herro scored 28 points and dished out 10 assists and Bam Adebayo added 17 points and 10 rebounds. It was the Heat's fourth game in a row without star Jimmy Butler , who sat out for what the team called “return to competition reconditioning.” Heat: Miami lost despite five players finishing with double-digit point totals. The Heat shot 44.4% from the field, but it wasn't enough to overcome a Hawks team that hit over half of its shots, 51.2% from the field. Hawks: Johnson has been on an offensive tear in his last two games. He finished two points shy of his single-game career high of 30 points, set in his last game, on Thursday against the Chicago Bulls. Hunter also finished just one point shy of his single-game career high of 27 points. After a close first half that featured nine lead changes, Atlanta seized control early in the second half. With five minutes to go in the third quarter, Atlanta’s Garrison Mathews and Hunter hit back-to-back 3s to give Atlanta an 81-72 lead, their biggest of the night, and forcing a Miami timeout. Young finished one assist shy of a franchise single-game record for assists against the Miami Heat, set by Mookie Blaylock in 1993. The Hawks begin a six-game road trip in Toronto on Sunday, while the Heat visits the Rockets on Sunday. AP NBA: https://apnews.com/hub/NBA
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenTribal Chiefs Demand Re-Run in Disputed Constituencies